Further compared to ccRCC and Mit family translocation RCC (tRCC), CDC had the significantly highest FUBP1 protein abundance and ribosome pathway score (Fig. 3L and Fig. S2K), indicating that the pharmacological targeting of FUBP1 might offer a promising therapeutic approach for CDC patients. The gene discussed is FUBP1; the disease is renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.